Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in Refractory/Intolerant GIST
NCT01391611Phase 2Terminated
- Start
- Jul 2011
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in gastrointestinal stromal tumor (GIST). Primary endpoint: Non-progression Rate Based on RECIST 1.0 Criteria (CR+PR+SD) at 24 weeks. Started Jul 2011; status: terminated.
02
Drugs
pazopanib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT01391611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01391611.